Overview
BMY market data
Price History
BMY price chart · 1M
- O
- 61.71
- H
- 62.91
- L
- 61.40
- C
- 62.89
- Vol
- 898,364.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $61.71
- Previous Close
- $61.51
- Day High
- $62.91
- Day Low
- $61.40
- 52 Week High
- $68.64
- 52 Week Low
- $52.84
- 7 Day Return
- -0.22%
- 30 Day Return
- -6.94%
- 90 Day Return
- +8.64%
- 1 Year Return
- +11.23%
- Daily Notional Volume
- $56.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 13.65 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.6% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 18.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.52 – $68.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $126.7B · P/B 5.94 · P/S 2.58.
Company News
10 captured
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsightGlobenewswire Inc ·
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend StocksZacks Investment Research ·
Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense networkGlobenewswire Inc ·
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Zacks Investment Research ·
Improve Your Retirement Income with These 3 Top-Ranked Dividend StocksZacks Investment Research ·